Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials is a research paper published in Clinical Genitourinary Cancer (2021). On theSindex it has a DataRank of 0.165. It has been cited 2 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.165
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →University of Texas MD Anderson Cancer Center
Grant: P30 CA016672
Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy
Grant: 1U01CA180964
Cancer Prevention and Research Institute of Texas
Grant: RP1100584
National Center for Advancing Translational Sciences
Grant: 1UL1TR000371
National Center for Advancing Translational Sciences
Grant: 1UL1TR003167
National Cancer Institute
Grant: R01CA242845-01A1
NCI NIH HHS
Grant: U01 CA180964
NCI NIH HHS
Grant: R01 CA242845
NCATS NIH HHS
Grant: UL1 TR000371
NCATS NIH HHS
Grant: UL1 TR003167
FWCI
0.20
Citation Percentile
0.5%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals